Table 1 Study design and baseline characteristics of included Studies.
Author (Year) | Marin (2021) [32] | Scalise (2020) [31] | Ott (2019) [30] | Prasad (2019) [29] | Hameed (2017) [28] | Hering (2017) [27] | Hoye (2017) [22] | Kiuchi (2015) [26] | Ott (2015) [25] | Schlaich (2013) [24] | Hering (2012) [23] |
|---|---|---|---|---|---|---|---|---|---|---|---|
Study Design | Single-arm Prospective | Prospective Comparative | Single-arm Prospective | Single-arm Prospective | Single-arm Prospective | Single-arm Prospective | Single-arm Prospective | Single-arm Prospective | Single-arm Prospective | Single-arm Prospective | Single-arm Prospective |
Country | Italy | Italy | Germany | Canada | United Kingdom | Australia | New Zealand | Brazil | Germany | Australia, Europe, USA | Australia |
CKD Stage | 3,4,5 | ESKD | ESKD | 3,4 | 3,4 | 3,4,5 | ESKD | 2,3,4 | 3,4 | ESKD | 3,4 |
F/U (months) | 12 | 12 | 6 | 24 | 6 | 24 | 12 | 24 | 12 | 12 | 6 |
Sample Size | 21 | 12 | 6 | 25 | 11 | 46 | 9 | 30 | 27 | 9 | 15 |
Age | 59.7 ± 17.1 | 56.5 ± 16.5 | 42.9 ± 27.9 | 62.8 ± 12.4 | 57.4 ± 14.4 | 66 ± 9 | 59 ± 9 | 55 ± 10 | 63.4 ± 9.4 | 47.4 ± 13.0a | 61 ± 9 |
%Males (n) | 85.7% (18) | 66.7% | 67% (4) | NR | 72.7% (8) | 61% (28) | 89% (8) | 43% (13) | 81% (22) | NR | 60% (9) |
Number Anti-HTN Drugs | 5.50 ± 0.90 | 4.80 ± 1.20 | 6.0 ± 0.47 | 4.9 ± 1.1 | 3.63 ± 0.84 | 4.9 ± 1.9 | 2.63 ± 2.62 | 4.6 ± 1.4 | 6.2 ± 1.1 | 4.20 ± 1.90 | 5.6 ± 1.3 |
% Diabetes (n) | 61.9% (13) | 33.3% | 17% (1) | NR | 45.5% (5) | 48% (22) | 22% (2) | 37% (11) | 56% (15) | NR | 73% (11) |
%CAD (n) | NR | NR | NR | NR | NR | 28% (13) | NR | 17% (5) | 37% (10) | NR | NR |
